Previous 10 | Next 10 |
Lucid Diagnostics Releases Positive Data Demonstrating Clinical Utility of EsoGuard® Esophageal Precancer Detection in Fire Fighters PR Newswire Study documents 100 percent concordance between EsoGuard ® test results and subsequent medical decision-making ...
Lucid Diagnostics Executes First Direct Employer Contract to Provide EsoGuard® Esophageal Precancer Testing as an Employee Benefit PR Newswire EsoGuard Testing now incorporated in Texas -based Ancira Auto Group's corporate Health and Wellness Program NEW YOR...
PAVmed Provides Business Update and Second Quarter Financial Results PR Newswire EsoGuard ® test volume continues to grow as Lucid makes strides with commercial expansion and additional supporting data Veris Health prepares to launch the next generation of the...
2023-08-15 12:38:03 ET Lucid Diagnostics Inc. (LUCD) Q2 2023 Results Conference Call August 15, 2023 8:30 AM ET Company Participants Michael Parks - VP, IR Lishan Aklog - Chairman, CEO Dennis McGrath - EVP, CFO Conference Call Participants Ed Woo - As...
2023-08-15 10:18:04 ET Lucid Diagnostics press release ( NASDAQ: LUCD ): Q2 Non-GAAP EPS of -$0.23 beats by $0.04 . Revenue of $0.16M. For further details see: Lucid Diagnostics Non-GAAP EPS of -$0.23 beats by $0.04, revenue of $0.16M
Lucid Diagnostics Provides Business Update and Second Quarter Financial Results PR Newswire Quarterly EsoGuard ® test volume increased 20 percent sequentially and 159 percent annually Revenue cycle management upgrade completed with immediate positive impact to...
PAVmed to Hold a Business Update Conference Call and Webcast on August 16, 2023 PR Newswire Conference Call and Webcast at 8:30 AM Eastern Time NEW YORK , July 31, 2023 /PRNewswire/ -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ ) ("PAVmed" or the "C...
Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on August 15, 2023 PR Newswire Conference Call and Webcast at 8:30AM Eastern Time NEW YORK , July 31, 2023 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Luci...
Lucid Diagnostics to Present at the Canaccord Genuity 43rd Annual Growth Conference PR Newswire NEW YORK , July 26, 2023 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid Diagnostics" or "Lucid"), a commercial-stage cancer prevention diagnostics c...
PAVmed and Lucid Chairman and Chief Executive Officer, Dr. Lishan Aklog, Testifies at U.S. House of Representatives Energy and Commerce Committee, Hearing on Life-Saving Innovations and Medicare Coverage PR Newswire Advocated stronger transparency and predictability, and inclu...
News, Short Squeeze, Breakout and More Instantly...
Lucid Diagnostics Inc. Company Name:
LUCD Stock Symbol:
NASDAQ Market:
Lucid Diagnostics Inc. Website:
Lucid Diagnostics Launches New Corporate Website PR Newswire NEW YORK , July 11, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and majority-ow...
Lucid Diagnostics Announces Positive Data from its ESOGUARD BE-1 Prospective, International, Multicenter Clinical Validation Study of EsoGuard® Esophageal Precancer Testing in a Screening Population PR Newswire Prospective screening study demonstrates excellent EsoGuard s...
4,000th Firefighter Undergoes Lucid Diagnostics' EsoGuard® Esophageal Precancer Testing PR Newswire Firefighter #CheckYourFoodTube Precancer Testing Event organized by Mass General Brigham physicians and Boston Firefighters Local 718 IAFF NEW YORK , June...